INTRODUCTION
Alzheimer's disease (AD) is a terminal dementing neurodegenerative disease that impacts on cognition and behaviour. [1] It is the most common form of dementia, affecting approximately 27 million people worldwide, [2] and incidence rates are expected to quadruple by the middle of this century. [3] Considerable interest and resources have been targeted at slowing AD progression as reflected in the growing number of clinical trials in AD. [4] The most widely used primary outcome measure in these clinical trials has been the AD Assessment Scale -Cognitive Behaviour Section (ADAS-cog). [5, 6] It was developed in the early 1980s in response to the then perceived lack of appropriate instruments available to test the efficacy of AD drug treatments, [5, 6] to assess the "severity of dysfunction and research in patients with Alzheimer's Disease". [6(p1360) ] Since its inception, the ADAS-cog has been used in over 127 AD clinical trials, and although developed specifically for AD, it has frequently been used in non-AD populations, including mild cognitive impairment, [7] vascular dementia, [8] and Parkinson's disease. [9] Of particular relevance to the present study is that clinical trials are increasingly focusing on people earlier in the disease process and with less severe AD. As awareness increases, diagnoses are likely to be made much earlier than they were 25 years ago.
If the ADAS-cog is to be considered fit for future measurement of all severities of AD including milder forms, it should satisfy stringent criteria as a reliable and valid measure of cognitive performance. Awareness of this issue is now widely recognised by international regulatory agencies concerning the use of patient rating scales. The ADAS-cog was developed with sound consideration of relevant neuropsychological consequences of AD, but without being subjected to rigorous psychometric techniques of rating scale construction. Although we are unsure as to the precise reasons the ADAS-Cog was developed in this way, the lack of standard rating scale construction methods may have resulted from a lack of awareness. As such, although these methods have existed for decades, they have been rarely applied to clinical rating scale research.
At its introduction, data on the ADAS-cog were provided on inter-rater and test-retest reliability in small samples of AD (n=27) and normal elderly (n=28). [6] Since then, it has undergone additional scale-level psychometric evaluations, [12] [13] [14] with some authors suggesting possible key limitations. [15, 16] The reason as to why psychometric evaluations of rating scales before their use are important requires a brief overview of the key issues surrounding the use of rating scales as outcomes measures.
Measurement requires the construction of an instrument for carrying out the practical process of measuring. Some variables, like height, can be measured directly and by relatively straightforward means. Other variables, like cognitive performance, need to be approached indirectly through quantifying their manifestations. It is important here to note that in its role as a clinical assessment tool the relevance of evaluating the ADAS-Cog using rating scale testing methods is appropriate but less crucial than to do so for its role as a measurement instrument for clinical research. This is because clinical assessment and measurement are different processes that have different requirements. We have previously summarised these, [11] but the key issue is that measurement has a specific meaning with respect to the quantification of attributes. By contrast, clinical assessment is, frequently, a qualitative process. Here instrument development is not straightforward and requires the construction of tools that transform numerically graded manifestations into measurements of underlying variables. Indirectly measured variables are often called latent (hidden) variables to emphasise this fact.
Rating scales are constructed to measure latent variables. It is customary for a rating scale to consist of a set of items, each of which represents a different manifestation. In relation to the ADAS-cog we have referred to these as components, as the eleven questions used are more detailed, time consuming and involved than traditional rating scale items. Every item is scored, and item scores are combined to give a total score for each person. This value is a measure of the variable quantified by the set of items.
Whether a rating scale generates clinically meaningful and scientifically sound measurements depends on decisions during its construction and its performance during testing. The decisions concern the components selected to form the set, their clinical grading and numerical scoring, and how components are combined to give a single value. Performance is tested against a number of predefined measurement (psychometric) criteria. This process appears clinically appropriate but requires empirical proof that it "works". This means that evidence is needed to support the choice of items forming the set, scoring of the individual items, and appropriateness of combining item scores into a single score. Also evidence should be available demonstrating that the single score is a reliable and valid measure of cognitive performance. Psychometric methods provide formal frameworks for gathering this evidence.
There are two main types of psychometric method; traditional and modern. [11] Traditional methods are the most widely used analytic strategy for determining rating scale reliability and validity and will be reported here. [17] These are the psychometric methods best understood by clinicians and clinical researchers, and underpin the forthcoming FDA guidelines for rating scales. [10] The aim of this study was to provide clinicians and researchers with a traditional psychometric evaluation of the ADAS-cog, which goes beyond the existing published examinations in type (ie detailed evaluations of data quality, scaling assumptions, targeting, reliability, validity) and kind (ie the inclusion of scale-and importantly component-level analyses).
METHODS

Setting and Participants
Anonymized screening and baseline data from three large clinical trials of donepezil [18] [19] [20] 
Data analysis
Many clinicians are familiar with reliability and validity testing, but a more thorough traditional psychometric evaluation involves the assessment of six properties: data quality, scaling assumptions, targeting, reliability, validity and responsiveness. Data completeness concerns the extent to which a scale's components are completed in the target sample, and the percent of people for whom it is possible to report a single score. Tests of scaling assumptions examine whether it is appropriate statistically to sum the 11 components to generate a single scale score. Targeting assesses the match between the range of cognitive performance measured by the ADAS-cog and the range of cognitive performance in the sample. Reliability describes the extent to which scale scores are free from random error. Validity refers to the extent to which the ADAS-cog measures cognitive performance. Responsiveness is the ability to detect accurately true change in cognitive performance when it has occurred. We examined five of these six psychometric propeties (see 
Psychometric properties
Data completeness (Tables 2&3) Data completeness was high. The proportion of component-level missing data was low (≤0.02%). ADAS-cog total scores could be computed for 99.7% of the sample (1418/1421). Tables 3, 4 and Appendix 3. In brief, data completeness includes percentage of missing data and computable scale scores; scaling assumptions involved tests of the legitimacy of summing components based on component means, standard deviations and item total correlations; targeting involved analyses of sccale score distributions; reliability included tests of random error including internal consistency and test retest reproducibility; validity invloved within and between scale correlational analyses and known groups analyses focussing on MMSE sub-samples. **<0.5% MD rounded to 0 ^Range ITC ***TRT between screening and baseline **** expanded in Table 4 
Comprehension
Data completeness
Component MD (%) Scaling Assumptions (Tables 2&3) The ADAS-cog satisfied most criteria for scaling assumptions. For example, componenttotal correlations (corrected for overlap) for the eleven ADAS-cog components ranged from 0.39-0.67 satisfying the recommended criteria. This supported the scale components as measures of a common underlying construct, and indicated that components contained a similar proportion of information about that construct.
However, Table 3 shows that ADAS-cog component mean scores and variances were not especially similar. Whilst this implies some criteria for scaling assumptions were not satisfied, it is important to note that ADAS-cog components have different numbers of response categories. Thus, mean scores and variances were similar for components with the same/similar numbers of response categories providing evidence that these criteria were fulfilled.
Targeting (Tables 2, 3 Validity (Table 2) Correlations between the ADAS-cog and MMSE were near our prediction at both screening (-0.63) and baseline (-0.74). Correlations between the ADAS-cog at baseline and sociodemographic variables (age and sex) were -0.01 and -0.07, respectively, indicating that ADAS-cog scores were not biased by these variables. These findings provided evidence for convergent and discriminant construct validity.
MMSE subgroups (10-14 moderately severe; 15-20 moderate; 21-26 mild; Table 4) Targeting analyses revealed that ADAS-cog component-level ceiling effects progressively increased as the severity of AD, measured by the MMSE, decreased (range: moderately severe -0-32%; moderate -0-59%; mild 0-82%; Table 4 ). Reliability, as assessed by Cronbach's alpha and test-retest ICCs were low (range 0.62 to 0.75 and 0.71-0.77, respectively). Finally, the examination of group differences validity revealed a stepwise decrease in ADAS-cog score as the MMSE score increases. The mean scores for the three groups are significantly different, in line with prediction (F=404.22, p<.0001). However, correlations between ADAS-cog and MMSE scores within each group were low to moderate (0.17 -0.49) and much lower than the predicted association between these two measures of cognitive performance, and that found in the total sample. 
DISCUSSION
At the scale level, the ADAS-cog met most traditional psychometric criteria in this large dataset of people with mild and mild-to-moderate AD, supporting the findings of previous research.[ 5 6 12 13] However, a closer examination of the component level findings, a form of analysis rarely undertaken in previous ADAS-cog research, [14] revealed suboptimal scale-to-sample targeting. The key issue here is that we would expect patients in this study to have a range of cognitive abilities. Despite this, over half the ADAS-cog components have substantial percentages of people (often >75%) scoring either 0 or 1, implying few or no problems in cognitive performance. As there is likely to be more clinical heterogeneity in patients' abilities than these components imply, this indicates a targeting problem, or mismatch, between the components' difficulties and patients' abilities in this sample. This is important because the limited component level targeting will impact on the overall ability of the ADAS-cog to detect cognitive differences between people and groups and potentially be less sensitive to the effects of interventions, as reflected in the findings of others. [14] Our findings demonstrate the importance of targeting rating scales to the individuals within a study sample. Specifically, the range of cognitive performance measured by the ADAS-cog should be well-matched to the range of cognitive performance present in the study sample so that the scale has the ability to detect variability among and within individuals. Poorly targeted scales most likely underestimate changes over time and differences between groups, which is particularly relevant for future AD clinical trials that are tending to recruit people with milder AD. The issue becomes more evident when targeting was examined in AD severity subgroups, demonstrating that the componentlevel ceiling effects progressively increased as the severity of AD decreased. This underscores the importance of examining component level targeting and demonstrates a misleading aspect of scalelevel results.
The problem of targeting could be improved by developing the components of the ADAS-cog so that they span a wider and more appropriate range of measurement. Although component-level floor and ceiling effects will almost always exist to some extent, they should be minimized if the potential of the ADAS-cog to detect change is to be maximized. However, although demonstrating these issues, the information provided by the traditional psychometric analyses used here does not provide specific guidance on how the ADAS-cog items might be improved. Alternative approaches are needed to elaborate upon these findings and propose an evidence-based strategy for restructuring and expanding the existing ADAS-cog components.
Results Our study has three key limitations. First, the dataset was formed from baseline and screening data from proprietary clinical trial data. It would be valuable to repeat these analyses in non-proprietary data, in other large datasets, to ensure generalisability of our findings to the wider mild to moderate AD population. Second, the current dataset did not allow for analyses of responsiveness to clinical change of cognitive performance over time. Although examinations of responsiveness will be useful to elaborate on and substantiate our present findings, they should not detract from addressing the component level targeting problems identified. Validity testing was also limited. In particular, we were restricted in the extent to which we could examine aspects of construct validity. Essentially, we were limited to using the MMSE as an external measure; a less detailed, and comprehensive measure of cognitive performance. Thus, further examinations would be beneficial, including head-to-head comparisons with other more comprehensive neuropsychological measures of cognitive performance.
A third limitation is, although the current dominant paradigm for rating scale testing procedures, traditional psychometric analyses have many clinically important limitations, which we have outlined in detail elsewhere. [11, 24] In relation to the current study there are two key issues.
First, these methods are sample and scale dependent. This is clearly seen when we compare the performance of the ADAS-cog in terms of scaling assumptions (range of item-total correlations), reliability (alphas, test-retest ICCs), and validity (correlations between the ADAS-cog and MMSE) in the three AD severity subgroups (as described above in the results above and presented in Table 4 ).
These results, if taken at face value, imply that the measurement performance of the ADAS-cog is AD severity dependent. However, the variability in results can be explained by the limited variance of the estimates in each subgroup. This is because traditional psychometric methods are largely based on correlational analyses, and correlations are strongly influenced by variability in the entities correlated.
Unfortunately, traditional psychometric methods do not enable us to determine if the differences detected are real (ie scale performance is dependent on AD severity) or simply an artefact of the data distributions. More sophisticated psychometric approaches, for example an analysis of differential item functioning using Rasch analysis, are required to make that distinction.
The second key issue relating to traditional psychometric analyses is that they provide limited information at the component level; particularly about the adequacy of the response options.
Importantly, there are concerns over the use of traditional analyses in scales (for discussion see reference 11), such as the ADAS-cog, that combine components with differing number and type of response categories. Therefore, once again, further examinations are required utilising newer sophisticated rating scale analysis techniques that overcome these limitations, such as Rasch measurement methods, [25, 26] to better diagnose the specific issues surrounding the performance of the ADAS-cog. [11] In this study, the ADAS-cog showed the potential to be a scientifically strong measurement instrument. However, our study also suggests that the ADAS-cog has limited ability to detect cognitive performance differences between people, changes over time, and the impact of treatment mild AD. Our analyses of the ADAS-cog by MMSE sub-group (Table 4) indicate that these limitations are more pronounced the milder forms of AD. The natural extrapolation of these findings is that the situation may be more problematic in people with mild cognitive impairment. Thus, in order for this scale to be a valuable cognitive performance measure in these patient groups, these limitations may need to be addressed.
Overall, although the ADAS-cog's psychometric performance was found to be satisfactory, more than half of its components may underestimate differences in cognitive performance in people with mild and moderate AD. The limited distributions indicate widespread targeting issues which may lead to problems in detecting clinical change when it occurs. This has important implications for the inferences of present and future clinical trials of AD using the ADAS-cog. Given the limitations of traditional psychometric methods, further evaluations would be desirable using more sophisticated modern rating scale analysis techniques to pinpoint the specific improvements that are required to maximise the ADAS-cog as a measure of cognitive performance in people with AD. words recalled correctly = 0, nine words recalled correctly = 1 ... none of the words recalled = 10; column 2) proportion (percentage) of patients endorsing each of the response options (column 2, as rated by the assessing clinician) for each of the eleven components of the ADAS-cog from the screening (column 3) and baseline (column 4) data.
